Conferencia en el CIB (Ojima)
30 de mayo de 2012 · Conferencias |
El Departamento de Biolog√≠a F√≠sico-Qu√≠mica os invita a participar en el siguiente seminario que se celebrar√° el VIERNES 1 de JUNIO a las 16:00 horas en el sal√≥n de actos del CIB.
Nuestro ponente es el Profesor Iwao Ojima del Department of Chemistry, State University of New York at Stony Brook y su seminario lleva por t√≠tulo: “Taxane-Based Tumor-Targeting Chemotherapeutic Agents”
El Profesor Iwao Ojima, Director del Institute of Chemical Biology and Drug Discovery (ICB&DD) de Stony Brook¬† es uno de los mayores expertos mundiales en el dise√Īo de agentes quimioterap√©uticos y en la b√ļsqueda de nuevas estrategias para aumentar sus propiedades farmacol√≥gicas.
University Distinguished Professor and Director
Department of Chemistry, State University of New York at Stony Brook
Director for the Institute of Chemical Biology and Drug Discovery (ICB&DD) at Stony Brook
His research interests include drug design and discovery (anticancer agents, antibacterial agents, enzyme inhibitors), medicinal chemistry and chemical biology, catalytic asymmetric synthesis, organic synthesis by means of organometallic reagents and catalysts, peptidomimetics, ő≤-lactam chemistry, and organofluorine chemistry (fluoroamino acids and peptides, medicinal applications). He has published more than 400 papers and reviews in leading journals and more than l50 patents and patent applications, edited 8 books (SciFinder lists >780 publications to his credits), and he has given more than 100 Plenary and Invited Lectures in international conferences and symposia by December 2011.
Taxane-based Tumor-Targeting Chemotherapeutic Agents
The long-standing problem in chemotherapy is the lack of tumor-specific treatments. Traditional chemotherapy relies on the premise that rapidly proliferating cancer cells are more likely to be killed by a cytotoxic agent. In reality, however, cytotoxic agents have very little or no specificity, which leads to systemic toxicity, causing undesirable severe side effects. Therefore, various ‚Äúmolecularly targeted cancer therapies‚ÄĚ have been developed for use in specific cancers, including tumor-targeting drug delivery (TTDD). In general, a TTDD system consists of a tumor recognition moiety and a cytotoxic warhead connected through a ‚Äúsmart‚ÄĚ linker to form a conjugate. When a multi-functionalized nanomaterial is used as the vehicle, a ‚ÄúTrojan Horse‚ÄĚ approach becomes possible for mass delivery of cytotoxic warheads to maximize the efficacy. We have recently discovered that new generation taxoids possess excellent activity against cancer stem cells from colon, prostate and breast cancers in addition to their high potency against bulk cancer cells and tumors. This lecture will present the progress in the novel molecular approaches to the design and development of ‚Äúguided molecular missiles‚ÄĚ for tumor-targeting chemotherapy using highly potent new generation taxoids as the warheads in our laboratory.